Opendata, web and dolomites

NIRCOThera SIGNED

Spatiotemporal, near-infrared light controlled carbon monoxide delivery for cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NIRCOThera project word cloud

Explore the words cloud of the NIRCOThera project. It provides you a very rough idea of what is the project "NIRCOThera" about.

genes    realize    single    unexploited    dependent    critical    therapeutic    time    treatment    herein    shown    microenvironment    walled    body    cardiovascular    metastasis    multiple    exposure    immune    infiltrating    reported    followed    corms    rebr3    sensitivity    models    triggered    carbon    tissues    manipulate    precision    animal    dose    cells    plan    functionalized    protein    toxicity    strategy    light       human    effect    health    biocompatibility    progress    net4    molecule    profile    rhenium    near    anti    manner    spatiotemporal    chemotherapy    monoxide    conjugate    clearance    cancer    purpose    generation    nir    platform    eradicate    relatively    lipid    largely    immunomodulatory    inflammation    molecules    cell    ultrahigh    bifunctional    expression    precise    reactive    swcnts    activation    exclusively       avenue    exogeneous    inflammatory    fast    stability    infrared    modulatory    naturally    nanotubes    signaling    disorders    consists    components    co    intratumoural    releasing    gaseous    progression    oxygen    loaded    expecting    chosen    vivo    angiogenesis    tumour    diseases    impart    tumours    combine    ready    sites    chemotherapeutics    excretion    site    ros    release    species   

Project "NIRCOThera" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

Carbon monoxide (CO) is a gaseous signaling molecule naturally produced by the human body. In recent years, CO has shown its anti-inflammatory and immunomodulatory properties and thus therapeutic potential in the treatment of inflammatory disorders and cardiovascular diseases. It is promising to exploit the modulatory effect of exogeneous CO in tumour microenvironment where inflammation and angiogenesis are the critical components of tumour progression and metastasis, which is largely unexploited. For this purpose, it is key to manipulate CO exposure in a precise dose and time-controlled manner exclusively at the tumour site. Herein, we propose to develop a new CO delivery avenue, enabling controlled CO release to tumour sites with spatiotemporal precision by using near infrared light (NIR). Specifically, the strategy consists of single-walled carbon nanotubes (SWCNTs) loaded with CO releasing molecules (CORMs). We have reported the development of a SWCNTs-based bifunctional system that enables intratumoural protein delivery and NIR activation, which is ready to be applied to realize controlled CO release in vivo. We plan to conjugate [ReBr3(CO)3][NEt4]2 to SWCNTs. The rhenium complex is chosen because of its stability and non-toxicity while the lipid functionalized SWCNTs have shown biocompatibility, ultrahigh tumour uptake and relatively fast clearance and excretion from the health tissues, which impart the platform promising for in vivo application. We will evaluate the stability of the platform, followed by the NIR-triggered CO release profile and then dose- and time-dependent effect on both cancer cells and tumour-infiltrating immune cells, including the generation of reactive oxygen species (ROS) and expression of multiple genes associated with tumour progress. Furthermore, expecting increased cancer cell sensitivity to chemotherapeutics with CO treatment, we will combine the proposed strategy with current chemotherapy to eradicate tumours in animal models.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NIRCOTHERA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NIRCOTHERA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

NarrowbandSSL (2019)

Development of Narrow Band Blue and Red Emitting Macromolecules for Solution-Processed Solid State Lighting Devices

Read More